About Esther Oliva, MD
She is a frequently invited guest speaker on subjects in her areas of expertise in the United States and around the world. She was the codirector of the GYN LONG COURSE in the 2015 United States and Canadian Academy of Pathology. She serves on the editorial board of the American Journal of Surgical Pathology, Archives of Pathology and Laboratory Medicine, Human Pathology, International Journal of Gynecologic Pathology, Advances in Anatomic Pathology, Modern Pathology, Seminars in Diagnostic Pathology, and Pathology (Australia). She is the secretary of the International Society of Gynecological Pathology. She has published over 150 peer-reviewed articles, is co-editor of the book "Gynecologic Pathology" (Foundations in Diagnostic Pathology series), editor of the monograph Current Concepts in Gynecologic Pathology: Mesenchymal Tumors of the Female Genital Tract and co-editor of the book Diagnostic Pathology Gynecologic from Amirsys, and has participated extensively in the latest WHO of Tumors of the Female Genital Tract. Her research is mainly focused on neoplastic diseases involving the female genital tract (with a particular interest in mesenchymal tumors at morphologic, translational and molecular levels) and the genitourinary tract.
Departments, Centers, & Programs:
Clinical Interests:
- Frozen Section Pathology
- Genitourinary pathology
- Gynecologic pathology
Treats:
- Adult
Languages:
- Catalan, Spanish
Locations
Mass General Pathology
55 Fruit St.
Boston, MA 02114
Phone: 617-643-0800
Medical Education
- MD, University of Barcelona
- Residency, Hospital de la Santa Creu i Sant Pau
- Residency, Massachusetts General Hospital
- Fellowship, Hospital Clinic I Provincial de Barcelona
- Fellowship, Hospital de la Santa Creu i Sant Pau
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Anatomic Pathology, American Board of Pathology
Accepted Insurance Plans
- Aetna
- Beech Street
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Cigna
- Commonwealth Care Alliance
- Coventry
- Fallon Health
- Harvard Pilgrim Health Care
- Humana
- Maine Community Health Options
- Mass General Brigham Health Plan
- MassHealth
- Medicaid CT
- Medicaid ME
- Medicaid NH
- Medicaid NY
- Medicaid RI
- Medicaid VT
- Medicare
- Medicare ACO
- Multiplan
- Railroad Medicare
- Senior Whole Health
- TriCare
- Tufts Health Plan
- United Health Care
- Wellpoint
- WellSense
- WellSense NH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
Research Interests include pathology and molecular biology of gynecologic malignancies, renal and testicular tumors. She is a member of the Gillette Center for Gynecologic Oncology's Clinical Research laboratory at the Massachusetts General Hospital Cancer Center. For more information about research concepts, co-authors, timeline, and more, visit Dr. Oliva's profile at the Harvard Clinical and Translational Science Center.
Publications
-
- Sclerosing Stromal Tumors With Prominent Luteinization During Pregnancy: A Report of 8 Cases Emphasizing Diagnostic Problems. Bennett JA, Oliva E, Young RH. Int J Gynecol Pathol. 2015 Apr 3. [Epub ahead of print]
- Giant Cell Tumor of the Uterus: A Report of 3 Cases With a Spectrum of Morphologic Features. Bennett JA, Sanada S, Selig MK, Hariri LP, Nielsen GP, Oliva E. Int J Gynecol Pathol. 2015 Apr 3. [Epub ahead of print]
- SMARCB1-deficient Vulvar Neoplasms: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 14 Cases.
Reviews: Comments and Ratings
Patient Gateway
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Adolescent and Young Adult (AYA) Cancer Program
The Adolescent and Young Adult Cancer Program was created to optimize the care, outcomes, and experiences of adolescent and young adult patients.
A Top Hospital in America
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2024-2025.